CDKN2A and head and neck squamous cell carcinoma: Currently, tumor mutations are not considered in the American Joint Committee on Cancer (AJCC) staging manual, nor are they considered in the National Comprehensive Cancer Network (NCCN) treatment guidelines for p16‐negative head and neck squamous cell carcinoma (HNSCC).